Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

IF THERE IS A RISK OF HARM THERE SHOULD BE CHOICE IN THE MATTER

https://rumble.com/vmgydn-wvuh-to-require-all-employees-to-be-vaccinated-or-will-face-voluntary-termi.html

RISK OF HARM???

https://rumble.com/vmx5rj-perth-australia-nurses-protest-vaccine-mandate.html

RISK OF HARM???

RISK OF HARM, WITH CHOICE???

Possible side effects include a sudden allergic reaction called anaphylaxis and IV-related reactions, fever, chills, hives, itching, and skin reddening or blotching.

https://www.webmd.com/lung/news/20201123/fda-authorizes-regeneron-covid-antibody-treatment

RISK OF HARM, WITH CHOICE???

Some side effects may occur during or up to 24 hours after the injection. Tell your caregiver right away if you have:

throat irritation, swelling in your face or throat;
fast, slow, or uneven heart rate;
confusion, dizziness, a light-headed feeling (like you might pass out);
chest pain, wheezing, shortness of breath;
fever, chills, sweating, nausea, weakness, tiredness;
pounding in your neck or ears;
rash, itching; or
headache, muscle pain. ———
Call your doctor if you have new or worsening symptoms after the infusion, such as fever, confusion, tiredness, feeling light-headed, irregular heartbeats, or trouble breathing.

https://www.everydayhealth.com/drugs/sotrovimab

CAN THE BEST OF EXPERIMENTAL VACCINES, OR OTHER, DO THIS???

Because of its lack of toxicity and low cost of manufacture compared to proprietary biologics, VIP may be uniquely attractive to those focused on global countermeasures against COVID-19, says the company.

VIP is known to target the VPAC1 receptor of the alveolar type II (ATII) cell and protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. In addition, VIP prevents apoptosis, blocks cytokines, lowers TNFa levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies.

https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-covid-19-therapeutic

ANY POTENTIAL BONUS???

One clinical use of VIP follows early diagnosis of dementia. Neuronal loss is rarely sudden; the time from detection of gray matter nuclear atrophy to when overt dementia begins can be long. VIP dosing at 300-600mcg/day, taken over 6-9 months has been shown to be safe and effective. We have shown (unpublished) that the mechanism of VIP correction of early dementia usually stems from correction of the unregulated over-expression of coagulation genes using VIP provides clinical benefit seen in a small, but ever-growing number of patients. In younger-aged Alzheimer’s patients, improvement coincides with correction of coagulation genes, which in turn reduces overproduction of coagulation gene products.

https://www.survivingmold.com/save-vip/additional-uses-of-vip